Each week we will aim to bring out a concise email that provides 4-5 key pieces of information addressing a specific issue in clinical therapeutics.
This week: Benralizumab – A New Treatment for Eosinophilic Asthma
Natalie Soulsby, Head of Clinical Development, Ward MM
Eosinophilic asthma is a sub-type of asthma usually found in those who develop asthma in adult hood. This type of asthma may not respond well to traditional treatments and can lead to air trapping, worsening of symptoms and frequent flare ups. It can have an impact on quality of life due to the persistent airway inflammation.
- Benralizumab (Faserna®) is a monoclonal antibody that is selective for IL-5 receptors and is licensed for treating eosinophilic asthma
- It’s indication for use is as add-on maintenance treatment for severe eosinophilic asthma in those with a blood eosinophil count of ≥ 300cells/microL or ≥ 150 cells/microL if on oral steroids
- Astra Zeneca who make Faserna® have agreed to allow early access to this treatment via a Product Familiarisation Program for qualified specialists as it is not currently available on the PBS
- It comes as an injection for sub cutaneous use. The starting dose is 30mg every 4 weeks for 3 doses and then the maintenance dose is every 8 weeks
- The most common side effects with this medication are headache and sore throat
Please consider these issues when preparing or interpreting RMMR reports or education sessions. Contributions of content or suggested topics are welcome and should be sent directly to email@example.com.